This Medudy course is a video tutorial for physicians on the topic "SDZ-Deno: A biosimilar to denosumab". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
The Sandoz biosimilar denosumab (SDZ-Deno) has been approved by the North American and European regulatory authorities for all indications of the reference product denosumab. By blocking RANKL, denosumab prevents bone resorption and loss of bone density and architecture. This mechanism is particularly beneficial in diseases characterized by excessive bone loss, such as osteoporosis in postmenopausal women and metastatic bone disease. This review highlights the totality of the evidence for SDZ-Deno.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
